Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BR101 in Relapsed/Refractory Multiple Myeloma
NCT07537049Phase 1Not yet recruiting
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
- Start
- Apr 2026
- Primary completion
- Apr 2027
- Modality
- Engineered Antibody Formats, Antibody Conjugates, Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ansipastobart in multiple myeloma (MM), sponsored by Cancer Institute and Hospital, Chinese Academy of Medical Sciences. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Planned start Apr 2026; status: not yet recruiting.
02
Drugs
ansipastobart
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on NCT07537049.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07537049.